ClinicalTrials.gg
CompletedNCT03105128Updated Jul 6, 2022Results posted

A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

A Phase 3 interventional study of placebo for risankizumab and risankizumab IV in Crohn's Disease, sponsored by AbbVie. Completed at 475 sites in 44 countries. Open to participants aged 16 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-07-06.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
931
Allocation
Randomized
Ages
16 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing risankizumab in Crohn Disease — 7 open to participants now, 10 under way, 6 of them phase 3. risankizumab · Crohn Disease.

Enrollment
3rd of 16
931 · median 275
Started
2017
with 1 other
Phase 3
8 of 16
3 open now
Registered
3rd of 16
by date
Lead sponsor
12 of 16
AbbVie

Among the 16 studies testing risankizumab in Crohn Disease, this one is the 3rd largest by enrollment, is one of 2 that started in 2017, is one of 8 in phase 3, and was the 3rd registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

7 of the 16 studies testing risankizumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About risankizumab

risankizumab: first FDA approval 2019 (SKYRIZI), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 16 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing risankizumab in Crohn Disease, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in participants with moderately to severely active Crohn's disease (CD).

03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • Crohn's Disease (CD)
  • Risankizumab
  • ABBV-066
  • BI 655066
04

Who can participate

Ages eligible
16 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged >=18 to \<= 80 years, or minimum age of adult consent according to local regulations, at the Baseline Visit. Where locally permissible, participants 16 to \< 18 years of age who meet the definition of Tanner stage 5 for development at the Baseline Visit.
  • Diagnosis of CD for at least 3 months prior to Baseline.
  • Confirmed diagnosis of moderate to severe CD as assessed by stool frequency (SF), abdominal pain (AP) score, and Simple Endoscopic Score for Crohn's Disease (SES-CD).
  • Demonstrated intolerance or inadequate response to conventional or to biologic therapy for CD.
  • If female, participant must meet the recommendations.

Exclusion criteria

Exclusion Criteria:

  • Participant with a current diagnosis of ulcerative colitis or indeterminate colitis.
  • Participants with unstable doses of concomitant Crohn's disease therapy.
  • Receipt of Crohn's disease approved biologic agents (infliximab, adalimumab, certolizumab, vedolizumab, natalizumab within 8 weeks prior to Baseline or ustekinumab within 12 weeks prior to Baseline), or any biologic or other agent or procedure within 35 days or 5 half-lives prior to Baseline, whichever is longer.
  • Prior exposure to p19 inhibitors (e.g., risankizumab).
  • Complications of Crohn's disease.
  • Having an ostomy or ileoanal pouch.
  • Known active Coronavirus Disease 2019 (COVID-19) infection.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
931 participants (actual)

Study arms

  • Experimental
    Risankizumab Dose 1 (Period 1)

    Participants randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion.

    Drug: risankizumab IV

  • Experimental
    Risankizumab Dose 2 (Period 1)

    Participants randomized to receive risankizumab dose 2 administered by intravenous (IV) infusion.

    Drug: risankizumab IV

  • Placebo comparator
    Placebo (Period 1)

    Participants randomized to receive placebo for risankizumab administered by intravenous (IV) infusion.

    Drug: placebo for risankizumab

  • Experimental
    Risankizumab Dose 1 (Period 2)

    Participants who received placebo in Period 1 and participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Period 2.

    Drug: risankizumab IV

  • Experimental
    Risankizumab Dose 2 (Period 2)

    Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection in Period 2.

    Drug: risankizumab SC

  • Experimental
    Risankizumab Dose 3 (Period 2)

    Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 3 administered by subcutaneous (SC) injection in Period 2.

    Drug: risankizumab SC

Interventions

  • Drugplacebo for risankizumab

    Placebo for risankizumab administered by intravenous infusion

  • Risankizumab administered by intravenous infusion

    Also known as: ABBV-066 BI 655066, SKYRIZI

  • Risankizumab administered by subcutaneous (SC) injection

    Also known as: ABBV-066 BI 655066, SKYRIZI

06

What researchers measure

Primary outcomes

  1. US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission

    The CDAI consists of 8 components; 7 are based on participant diary entries, participant interviews, physical examinations, measurement of body weight and height and 1 is based on laboratory analysis. CDAI clinical remission of Crohn's disease is defined as CDAI \< 150.

    Time frame: Week 12

  2. US Specific: Percentage of Participants With Endoscopic Response

    The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD \> 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).

    Time frame: Week 12

  3. Global Outside of US: Percentage of Participants With Clinical Remission

    Clinical remission is defined as using the average daily Stool Frequency (SF) ≤ 2.8 and not worse than Baseline AND average daily Abdominal Pain (AP) score ≤ 1 and not worse than Baseline.

    Time frame: Week 12

  4. Global Outside of US: Percentage of Participants With Endoscopic Response

    The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD \> 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).

    Time frame: Week 12

Secondary outcomes

  1. US Specific: Percentage of Participants With Clinical Remission

    Clinical remission is defined as using the average daily Stool Frequency (SF) ≤ 2.8 and not worse than Baseline AND average daily Abdominal Pain (AP) score ≤ 1 and not worse than Baseline.

    Time frame: Week 12

  2. US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response

    Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline.

    Time frame: Week 4

  3. US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response

    Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline.

    Time frame: Week 12

  4. US Specific: Change From Baseline of Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue

    The FACIT-Fatigue scale is a 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four point Likert scale. The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from baseline indicates improvement.

    Time frame: Week 12

  5. US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission

    Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical remission of Crohn's disease is defined as CDAI \< 150.

    Time frame: Week 4

  6. US Specific: Percentage of Participants With CDAI Clinical Response and Endoscopic Response

    Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline. Endoscopic response was a decrease in Simplified Endoscopic Score for Crohn's Disease (SES-CD) \> 50% from Baseline (or for subjects with isolated ileal disease and a Baseline SES-CD of 4, at least a 2 point reduction from Baseline).

    Time frame: Week 12

  7. US Specific: Percentage of Participants With Stool Frequency (SF) Remission

    Stool Frequency (SF) remission is defined as an average daily SF \<= 2.8 and not worse than baseline.

    Time frame: Week 12

  8. US Specific: Percentage of Participants With Abdominal Pain (AP) Remission

    The Abdominal Pain rating is an assessment that is graded from 0 to 3: 0= None, 1= Mild, 2= Moderate and 3= Severe. AP remission is defined as average daily AP score \<= 1 and not worse than baseline.

    Time frame: Week 12

  9. US Specific: Percentage of Participants With Endoscopic Remission

    Endoscopic remission: SES-CD ≤ 4 and at least a 2 point reduction versus baseline and no subscore greater than 1 in any individual variable

    Time frame: Week 12

  10. US Specific: Percentage of Participants With Enhanced Clinical Response

    Enhanced clinical response: ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission

    Time frame: Week 4

  11. US Specific: Percentage of Participants With Ulcer-Free Endoscopy

    Ulcer-free endoscopy: SES-CD ulcerated surface subscore of 0 in subjects with SES-CD ulcerated surface subscore ≥ 1 at Baseline

    Time frame: Week 12

  12. US Specific: Percentage of Participants With Enhanced Clinical Response

    Enhanced clinical response: ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission

    Time frame: Week 12

  13. US Specific: Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs), in Participants With EIMs at

    Manifestations of Crohn's disease in areas of the body other than the digestive tract, including eyes, skin, joints, mouth, and liver.

    Time frame: Week 12

  14. US Specific: Percentage of Participants With CD-Related Hospitalization

    Participants with at least one admission to the hospital due to Crohn's Disease.

    Time frame: Week 12

  15. US Specific: Percentage of Participants Without Draining Fistulas in Participants With Draining Fistulas at Baseline

    Participants without draining fistulas at Week 12 in participants who had draining fistulas at baseline.

    Time frame: Week 12

  16. Global Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission

    The CDAI consists of 8 components; 6 are based on participant diary entries, participant interviews, and physical examinations, and 2 are based on laboratory analysis, and measurement of body weight and height. CDAI clinical remission of Crohn's disease is defined as CDAI \< 150.

    Time frame: Week 12

  17. Global Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response

    Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline.

    Time frame: Week 4

  18. Global Outside of US: Percentage of Participants With Clinical Remission

    Clinical remission is defined as using the average daily Stool Frequency (SF) ≤ 2.8 and not worse than Baseline AND average daily Abdominal Pain (AP) score ≤ 1 and not worse than Baseline.

    Time frame: Week 4

  19. Global Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response

    Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline.

    Time frame: Week 12

  20. Global Outside of US: Change From Baseline of Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue

    The FACIT-Fatigue scale is a 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four point Likert scale. The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from baseline indicates improvement.

    Time frame: Week 12

  21. Global Outside of US: Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score

    The IBDQ is a 32-item (ranges 1 - 7) self-report questionnaire for patients with IBD to evaluate the patient reported outcomes across 4 dimensions: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). The IBDQ total Score ranges from 32 to 224 with a higher score indicating better outcome.

    Time frame: Week 12

  22. Global Outside of US: Percentage of Participants With Enhanced Clinical Response and Endoscopic Response

    Enhanced clinical response was defined as ≥ 60% decrease in average daily Stool Frequency and/or ≥ 35% decrease in average daily Abdominal Pain score and both not worse than baseline, and/or clinical remission. Endoscopic Response was defined as a decrease in Simplified Endoscopic Score for Crohn's Disease (SES-CD) \> 50% from Baseline (or for subjects with isolated ileal disease and a Baseline SES-CD of 4, at least a 2 point reduction from Baseline).

    Time frame: Week 12

  23. Global Outside of US: Percentage of Participants With Endoscopic Remission

    Endoscopic remission: SES-CD ≤ 4 and at least a 2 point reduction versus baseline and no subscore greater than 1 in any individual variable

    Time frame: Week 12

  24. Global Outside of US: Percentage of Participants With Enhanced Clinical Response

    Enhanced clinical response: ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission

    Time frame: Week 4

  25. Global Outside of US: Percentage of Participants With Ulcer-Free Endoscopy

    Ulcer-free endoscopy: SES-CD ulcerated surface subscore of 0 in subjects with SES-CD ulcerated surface subscore ≥ 1 at Baseline

    Time frame: Week 12

  26. Global Outside of US: Percentage of Participants With Enhanced Clinical Response

    Enhanced clinical response: ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission

    Time frame: Week 12

  27. Global Outside of US: Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs), in Participants With EIMs at Baseline

    Manifestations of Crohn's disease in areas of the body other than the digestive tract, including eyes, skin, joints, mouth, and liver.

    Time frame: Week 12

  28. Global Outside of US: Percentage of Participants With CD-Related Hospitalization

    Participants with at least one admission to the hospital due to Crohn's Disease.

    Time frame: Week 12

  29. Global Outside of US: Percentage of Participants Without Draining Fistulas in Participants With Draining Fistulas at Baseline

    Participants without draining fistulas at Week 12 in participants who had draining fistulas at baseline.

    Time frame: Week 12

  30. Global Outside of US: Change From Baseline in Work Productivity and Impairment Questionnaire - Crohn's Disease (WPAI-CD) Overall Work Impairment

    WPAI: CD is a questionnaire used to evaluate lost productivity due to CD ; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. Total work productivity impairment takes into account both hours missed due to CD symptoms and the patient's assessment of the degree to which CD affected their productivity while working (overall work impairment \[OWI\]). WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.

    Time frame: Week 12

  31. Global Outside of US: Change From Baseline in Short Form-36 (SF-36) Physical Component Summary (PCS) Score

    The Short Form-36 Health Survey determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement.

    Time frame: Week 12

07

Results

Posted Jul 6, 2022

Participant flow

Subjects were randomized to receive 600mg risankizumab, 1200mg risankizumab or placebo during the double-blind, placebo-controlled Period 1. At Week 12, subjects who do not achieve clinical response were randomized into Period 2 to receive 180mg risankizumab, 360mg risankizumab or 1200mg risankizumab. Subjects who received placebo received 1200mg.

Period 1
Participant flow — Period 1
MilestoneRisankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)Placebo (Induction Period 1)Risankizumab 180mg (Induction Period 2)Risankizumab 360mg (Induction Period 2)Risankizumab 1200mg (Induction Period 2)Placebo/Risankizumab IV (Induction Period 2)
Started3733721860000
Completed3653661630000
Not completed86230000
Period 2
Participant flow — Period 2
MilestoneRisankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)Placebo (Induction Period 1)Risankizumab 180mg (Induction Period 2)Risankizumab 360mg (Induction Period 2)Risankizumab 1200mg (Induction Period 2)Placebo/Risankizumab IV (Induction Period 2)
Started00067686776
Completed00062656474
Not completed0005332

Outcome measures

PrimaryUS Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission

The CDAI consists of 8 components; 7 are based on participant diary entries, participant interviews, physical examinations, measurement of body weight and height and 1 is based on laboratory analysis. CDAI clinical remission of Crohn's disease is defined as CDAI \< 150.

Time frame:
Week 12
Reported as:
Number · percentage of participants
US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission
percentage of participantsPlacebo (Period 1)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)
US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission24.6 (18.2 to 31.0)45.2 (39.9 to 50.5)41.6 (36.3 to 46.8)
Statistical analysis
  • Placebo (Period 1) vs Risankizumab 600mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 20.7 · 95% CI 12.4 to 29.0
  • Placebo (Period 1) vs Risankizumab 1200mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 16.7 · 95% CI 8.5 to 24.9
PrimaryUS Specific: Percentage of Participants With Endoscopic Response

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD \> 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).

Time frame:
Week 12
Reported as:
Number · percentage of participants
US Specific: Percentage of Participants With Endoscopic Response
percentage of participantsPlacebo (Period 1)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)
US Specific: Percentage of Participants With Endoscopic Response12.0 (7.2 to 16.8)40.3 (35.0 to 45.6)32.1 (27.1 to 37.1)
Statistical analysis
  • Placebo (Period 1) vs Risankizumab 600mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 28.3 · 95% CI 21.2 to 35.4
  • Placebo (Period 1) vs Risankizumab 1200mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 20.3 · 95% CI 13.6 to 27.1
PrimaryGlobal Outside of US: Percentage of Participants With Clinical Remission

Clinical remission is defined as using the average daily Stool Frequency (SF) ≤ 2.8 and not worse than Baseline AND average daily Abdominal Pain (AP) score ≤ 1 and not worse than Baseline.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Global Outside of US: Percentage of Participants With Clinical Remission
percentage of participantsPlacebo (Period 1)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)
Global Outside of US: Percentage of Participants With Clinical Remission21.7 (15.6 to 27.8)43.5 (38.2 to 48.8)41.0 (35.8 to 46.2)
Statistical analysis
  • Placebo (Period 1) vs Risankizumab 600mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 21.9 · 95% CI 13.8 to 29.9
  • Placebo (Period 1) vs Risankizumab 1200mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 18.8 · 95% CI 10.8 to 26.8
PrimaryGlobal Outside of US: Percentage of Participants With Endoscopic Response

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD \> 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).

Time frame:
Week 12
Reported as:
Number · percentage of participants
Global Outside of US: Percentage of Participants With Endoscopic Response
percentage of participantsPlacebo (Period 1)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)
Global Outside of US: Percentage of Participants With Endoscopic Response12.0 (7.2 to 16.8)40.3 (35.0 to 45.6)32.1 (27.1 to 37.1)
Statistical analysis
  • Placebo (Period 1) vs Risankizumab 600mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 28.3 · 95% CI 21.2 to 35.4
  • Placebo (Period 1) vs Risankizumab 1200mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 20.3 · 95% CI 13.6 to 27.1
SecondaryUS Specific: Percentage of Participants With Clinical Remission

Clinical remission is defined as using the average daily Stool Frequency (SF) ≤ 2.8 and not worse than Baseline AND average daily Abdominal Pain (AP) score ≤ 1 and not worse than Baseline.

Time frame:
Week 12
Reported as:
Number · percentage of participants
US Specific: Percentage of Participants With Clinical Remission
percentage of participantsPlacebo (Period 1)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)
US Specific: Percentage of Participants With Clinical Remission21.7 (15.6 to 27.8)43.5 (38.2 to 48.8)41.0 (35.8 to 46.2)
Statistical analysis
  • Placebo (Period 1) vs Risankizumab 600mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 21.9 · 95% CI 13.8 to 29.9
  • Placebo (Period 1) vs Risankizumab 1200mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 18.8 · 95% CI 10.8 to 26.8
SecondaryUS Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response

Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline.

Time frame:
Week 4
Reported as:
Number · percentage of participants
US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response
percentage of participantsPlacebo (Period 1)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)
US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response25.2 (18.7 to 31.6)40.8 (35.5 to 46.0)37.2 (32.0 to 42.3)
Statistical analysis
  • Placebo (Period 1) vs Risankizumab 600mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 15.4 · 95% CI 7.2 to 23.7
  • Placebo (Period 1) vs Risankizumab 1200mg (Period 1) · Cochran-Mantel-Haenszel · p = 0.007 · Adjusted risk difference: 11.2 · 95% CI 3.1 to 19.2
SecondaryUS Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response

Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline.

Time frame:
Week 12
Reported as:
Number · percentage of participants
US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response
percentage of participantsPlacebo (Period 1)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)
US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response36.7 (29.6 to 43.9)59.7 (54.5 to 65.0)64.9 (59.8 to 70.0)
Statistical analysis
  • Placebo (Period 1) vs Risankizumab 600mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 23.1 · 95% CI 14.2 to 31.9
  • Placebo (Period 1) vs Risankizumab 1200mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 27.7 · 95% CI 19.0 to 36.4
SecondaryUS Specific: Change From Baseline of Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue

The FACIT-Fatigue scale is a 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four point Likert scale. The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from baseline indicates improvement.

Time frame:
Week 12
Reported as:
Least squares mean · percentage of participants
US Specific: Change From Baseline of Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue
percentage of participantsPlacebo (Period 1)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)
US Specific: Change From Baseline of Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue6.0 (4.4 to 7.7)11.2 (10.1 to 12.4)10.1 (9.0 to 11.3)
Statistical analysis
  • Placebo (Period 1) vs Risankizumab 600mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 5.2 · 95% CI 3.2 to 7.2
  • Placebo (Period 1) vs Risankizumab 1200mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 4.1 · 95% CI 2.1 to 6.1
SecondaryUS Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission

Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical remission of Crohn's disease is defined as CDAI \< 150.

Time frame:
Week 4
Reported as:
Number · percentage of participants
US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission
percentage of participantsPlacebo (Period 1)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)
US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission10.3 (5.8 to 14.8)18.4 (14.3 to 22.6)18.9 (14.7 to 23.0)
Statistical analysis
  • Placebo (Period 1) vs Risankizumab 600mg (Period 1) · Cochran-Mantel-Haenszel · p = 0.015 · Adjusted risk difference: 7.6 · 95% CI 1.5 to 13.7
  • Placebo (Period 1) vs Risankizumab 1200mg (Period 1) · Cochran-Mantel-Haenszel · p = 0.007 · Adjusted risk difference: 8.4 · 95% CI 2.3 to 14.6
SecondaryUS Specific: Percentage of Participants With CDAI Clinical Response and Endoscopic Response

Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline. Endoscopic response was a decrease in Simplified Endoscopic Score for Crohn's Disease (SES-CD) \> 50% from Baseline (or for subjects with isolated ileal disease and a Baseline SES-CD of 4, at least a 2 point reduction from Baseline).

Time frame:
Week 12
Reported as:
Number · percentage of participants
US Specific: Percentage of Participants With CDAI Clinical Response and Endoscopic Response
percentage of participantsPlacebo (Period 1)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)
US Specific: Percentage of Participants With CDAI Clinical Response and Endoscopic Response5.7 (2.3 to 9.2)30.0 (25.1 to 34.9)23.0 (18.5 to 27.5)
Statistical analysis
  • Placebo (Period 1) vs Risankizumab 600mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 24.5 · 95% CI 18.5 to 30.5
  • Placebo (Period 1) vs Risankizumab 1200mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 17.3 · 95% CI 11.8 to 22.9
SecondaryUS Specific: Percentage of Participants With Stool Frequency (SF) Remission

Stool Frequency (SF) remission is defined as an average daily SF \<= 2.8 and not worse than baseline.

Time frame:
Week 12
Reported as:
Number · percentage of participants
US Specific: Percentage of Participants With Stool Frequency (SF) Remission
percentage of participantsPlacebo (Period 1)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)
US Specific: Percentage of Participants With Stool Frequency (SF) Remission29.8 (23.1 to 36.6)54.2 (48.8 to 59.5)54.0 (48.7 to 59.3)
Statistical analysis
  • Placebo (Period 1) vs Risankizumab 600mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 24.2 · 95% CI 15.7 to 32.7
  • Placebo (Period 1) vs Risankizumab 1200mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 23.6 · 95% CI 15.1 to 32.1
SecondaryUS Specific: Percentage of Participants With Abdominal Pain (AP) Remission

The Abdominal Pain rating is an assessment that is graded from 0 to 3: 0= None, 1= Mild, 2= Moderate and 3= Severe. AP remission is defined as average daily AP score \<= 1 and not worse than baseline.

Time frame:
Week 12
Reported as:
Number · percentage of participants
US Specific: Percentage of Participants With Abdominal Pain (AP) Remission
percentage of participantsPlacebo (Period 1)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)
US Specific: Percentage of Participants With Abdominal Pain (AP) Remission38.5 (31.2 to 45.7)59.6 (54.3 to 64.8)58.1 (52.9 to 63.4)
Statistical analysis
  • Placebo (Period 1) vs Risankizumab 600mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 21.2 · 95% CI 12.4 to 30.0
  • Placebo (Period 1) vs Risankizumab 1200mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 19.0 · 95% CI 10.1 to 27.8
SecondaryUS Specific: Percentage of Participants With Endoscopic Remission

Endoscopic remission: SES-CD ≤ 4 and at least a 2 point reduction versus baseline and no subscore greater than 1 in any individual variable

Time frame:
Week 12
Reported as:
Number · percentage of participants
US Specific: Percentage of Participants With Endoscopic Remission
percentage of participantsPlacebo (Period 1)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)
US Specific: Percentage of Participants With Endoscopic Remission9.1 (4.9 to 13.4)24.2 (19.6 to 28.7)23.9 (19.4 to 28.5)
Statistical analysis
  • Placebo (Period 1) vs Risankizumab 600mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 15.1 · 95% CI 9.0 to 21.2
  • Placebo (Period 1) vs Risankizumab 1200mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 15.4 · 95% CI 9.4 to 21.4
SecondaryUS Specific: Percentage of Participants With Enhanced Clinical Response

Enhanced clinical response: ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission

Time frame:
Week 4
Reported as:
Number · percentage of participants
US Specific: Percentage of Participants With Enhanced Clinical Response
percentage of participantsPlacebo (Period 1)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)
US Specific: Percentage of Participants With Enhanced Clinical Response31.0 (24.1 to 37.9)46.0 (40.7 to 51.3)43.4 (38.1 to 48.6)
Statistical analysis
  • Placebo (Period 1) vs Risankizumab 600mg (Period 1) · Cochran-Mantel-Haenszel · p = 0.001 · Adjusted risk difference: 14.9 · 95% CI 6.2 to 23.5
  • Placebo (Period 1) vs Risankizumab 1200mg (Period 1) · Cochran-Mantel-Haenszel · p = 0.007 · Adjusted risk difference: 11.8 · 95% CI 3.2 to 20.3
SecondaryUS Specific: Percentage of Participants With Ulcer-Free Endoscopy

Ulcer-free endoscopy: SES-CD ulcerated surface subscore of 0 in subjects with SES-CD ulcerated surface subscore ≥ 1 at Baseline

Time frame:
Week 12
Reported as:
Number · percentage of participants
US Specific: Percentage of Participants With Ulcer-Free Endoscopy
percentage of participantsPlacebo (Period 1)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)
US Specific: Percentage of Participants With Ulcer-Free Endoscopy7.6 (3.6 to 11.5)21.0 (16.6 to 25.4)16.4 (12.4 to 20.3)
Statistical analysis
  • Placebo (Period 1) vs Risankizumab 600mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 13.7 · 95% CI 7.9 to 19.5
  • Placebo (Period 1) vs Risankizumab 1200mg (Period 1) · Cochran-Mantel-Haenszel · p = 0.001 · Adjusted risk difference: 9.1 · 95% CI 3.7 to 14.5
SecondaryUS Specific: Percentage of Participants With Enhanced Clinical Response

Enhanced clinical response: ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission

Time frame:
Week 12
Reported as:
Number · percentage of participants
US Specific: Percentage of Participants With Enhanced Clinical Response
percentage of participantsPlacebo (Period 1)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)
US Specific: Percentage of Participants With Enhanced Clinical Response41.9 (34.6 to 49.3)62.8 (57.6 to 68.0)64.3 (59.2 to 69.4)
Statistical analysis
  • Placebo (Period 1) vs Risankizumab 600mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 21.0 · 95% CI 12.2 to 29.9
  • Placebo (Period 1) vs Risankizumab 1200mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 21.6 · 95% CI 12.8 to 30.4
SecondaryUS Specific: Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs), in Participants With EIMs at

Manifestations of Crohn's disease in areas of the body other than the digestive tract, including eyes, skin, joints, mouth, and liver.

Time frame:
Week 12
Reported as:
Number · percentage of participants
US Specific: Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs), in Participants With EIMs at
percentage of participantsPlacebo (Period 1)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)
US Specific: Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs), in Participants With EIMs at20.5 (10.5 to 30.4)38.1 (30.0 to 46.1)43.7 (35.9 to 51.4)
Statistical analysis
  • Placebo (Period 1) vs Risankizumab 600mg (Period 1) · Cochran-Mantel-Haenszel · p = 0.022 · Adjusted risk difference: 14.6 · 95% CI 2.1 to 27.0
  • Placebo (Period 1) vs Risankizumab 1200mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 23.7 · 95% CI 11.1 to 36.3
SecondaryUS Specific: Percentage of Participants With CD-Related Hospitalization

Participants with at least one admission to the hospital due to Crohn's Disease.

Time frame:
Week 12
Reported as:
Number · percentage of participants
US Specific: Percentage of Participants With CD-Related Hospitalization
percentage of participantsPlacebo (Period 1)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)
US Specific: Percentage of Participants With CD-Related Hospitalization12.0 (7.2 to 16.8)3.3 (1.4 to 5.2)1.8 (0.4 to 3.2)
Statistical analysis
  • Placebo (Period 1) vs Risankizumab 600mg (Period 1) · Chi-squared · p = <0.001 · Risk difference (rd): -8.7 · 95% CI -13.9 to -3.5
  • Placebo (Period 1) vs Risankizumab 1200mg (Period 1) · Chi-squared · p = <0.001 · Risk difference (rd): -10.2 · 95% CI -15.2 to -5.2
SecondaryUS Specific: Percentage of Participants Without Draining Fistulas in Participants With Draining Fistulas at Baseline

Participants without draining fistulas at Week 12 in participants who had draining fistulas at baseline.

Time frame:
Week 12
Reported as:
Number · percentage of participants
US Specific: Percentage of Participants Without Draining Fistulas in Participants With Draining Fistulas at Baseline
percentage of participantsPlacebo (Period 1)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)
US Specific: Percentage of Participants Without Draining Fistulas in Participants With Draining Fistulas at Baseline22.2 (0.0 to 49.4)27.8 (7.1 to 48.5)29.2 (11.0 to 47.4)
Statistical analysis
  • Placebo (Period 1) vs Risankizumab 600mg (Period 1) · Chi-squared · p = 1.00 · Risk difference (rd): 5.6 · 95% CI -28.6 to 39.7
  • Placebo (Period 1) vs Risankizumab 1200mg (Period 1) · Chi-squared · p = 1.000 · Risk difference (rd): 6.9 · 25% CI -25.7 to 39.6
SecondaryGlobal Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission

The CDAI consists of 8 components; 6 are based on participant diary entries, participant interviews, and physical examinations, and 2 are based on laboratory analysis, and measurement of body weight and height. CDAI clinical remission of Crohn's disease is defined as CDAI \< 150.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Global Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission
percentage of participantsPlacebo (Period 1)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)
Global Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission24.6 (18.2 to 31.0)45.2 (39.9 to 50.5)41.6 (36.3 to 46.8)
Statistical analysis
  • Placebo (Period 1) vs Risankizumab 600mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 20.7 · 95% CI 12.4 to 29.0
  • Placebo (Period 1) vs Risankizumab 1200mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 16.7 · 95% CI 8.5 to 24.9
SecondaryGlobal Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response

Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Global Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response
percentage of participantsPlacebo (Period 1)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)
Global Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response25.2 (18.7 to 31.6)40.8 (35.5 to 46.0)37.2 (32.0 to 42.3)
Statistical analysis
  • Placebo (Period 1) vs Risankizumab 600mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 15.4 · 95% CI 7.2 to 23.7
  • Placebo (Period 1) vs Risankizumab 1200mg (Period 1) · Cochran-Mantel-Haenszel · p = 0.007 · Adjusted risk difference: 11.2 · 95% CI 3.1 to 19.2
SecondaryGlobal Outside of US: Percentage of Participants With Clinical Remission

Clinical remission is defined as using the average daily Stool Frequency (SF) ≤ 2.8 and not worse than Baseline AND average daily Abdominal Pain (AP) score ≤ 1 and not worse than Baseline.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Global Outside of US: Percentage of Participants With Clinical Remission
percentage of participantsPlacebo (Period 1)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)
Global Outside of US: Percentage of Participants With Clinical Remission9.1 (4.9 to 13.4)21.0 (16.6 to 25.3)21.2 (16.9 to 25.6)
Statistical analysis
  • Placebo (Period 1) vs Risankizumab 600mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 11.5 · 95% CI 5.4 to 17.5
  • Placebo (Period 1) vs Risankizumab 1200mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 11.7 · 95% CI 5.7 to 17.8
SecondaryGlobal Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response

Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Global Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response
percentage of participantsPlacebo (Period 1)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)
Global Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response36.7 (29.6 to 43.9)59.7 (54.5 to 65.0)64.9 (59.8 to 70.0)
Statistical analysis
  • Placebo (Period 1) vs Risankizumab 600mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 23.1 · 95% CI 14.2 to 31.9
  • Placebo (Period 1) vs Risankizumab 1200mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 27.7 · 95% CI 19.0 to 36.4
SecondaryGlobal Outside of US: Change From Baseline of Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue

The FACIT-Fatigue scale is a 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four point Likert scale. The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from baseline indicates improvement.

Time frame:
Week 12
Reported as:
Least squares mean · units on a scale
Global Outside of US: Change From Baseline of Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue
units on a scalePlacebo (Period 1)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)
Global Outside of US: Change From Baseline of Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue6.0 (4.4 to 7.7)11.2 (10.1 to 12.4)10.1 (9.0 to 11.3)
Statistical analysis
  • Placebo (Period 1) vs Risankizumab 600mg (Period 1) · Mixed-Effect Model Repeat Measurement · p = <0.001 · Ls mean difference: 5.2 · 95% CI 3.2 to 7.2
  • Placebo (Period 1) vs Risankizumab 1200mg (Period 1) · Mixed-Effect Model Repeat Measurement · p = <0.001 · Ls mean difference: 4.1 · 95% CI 2.1 to 6.1
SecondaryGlobal Outside of US: Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score

The IBDQ is a 32-item (ranges 1 - 7) self-report questionnaire for patients with IBD to evaluate the patient reported outcomes across 4 dimensions: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). The IBDQ total Score ranges from 32 to 224 with a higher score indicating better outcome.

Time frame:
Week 12
Reported as:
Mean · units on a scale
Global Outside of US: Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score
units on a scalePlacebo (Period 1)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)
Global Outside of US: Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score23.6 (18.2 to 28.9)44.3 (40.6 to 48.0)43.0 (39.4 to 46.6)
Statistical analysis
  • Placebo (Period 1) vs Risankizumab 600mg (Period 1) · Mixed-Effect Model Repeat Measurement · p = <0.001 · Ls mean difference: 20.7 · 95% CI 14.3 to 27.1
  • Placebo (Period 1) vs Risankizumab 1200mg (Period 1) · Mixed-Effect Model Repeat Measurement · p = <0.001 · Ls mean difference: 19.4 · 95% CI 13.1 to 25.8
SecondaryGlobal Outside of US: Percentage of Participants With Enhanced Clinical Response and Endoscopic Response

Enhanced clinical response was defined as ≥ 60% decrease in average daily Stool Frequency and/or ≥ 35% decrease in average daily Abdominal Pain score and both not worse than baseline, and/or clinical remission. Endoscopic Response was defined as a decrease in Simplified Endoscopic Score for Crohn's Disease (SES-CD) \> 50% from Baseline (or for subjects with isolated ileal disease and a Baseline SES-CD of 4, at least a 2 point reduction from Baseline).

Time frame:
Week 12
Reported as:
Number · percentage of participants
Global Outside of US: Percentage of Participants With Enhanced Clinical Response and Endoscopic Response
percentage of participantsPlacebo (Period 1)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)
Global Outside of US: Percentage of Participants With Enhanced Clinical Response and Endoscopic Response8.0 (4.0 to 12.0)30.9 (25.9 to 35.8)23.2 (18.7 to 27.8)
Statistical analysis
  • Placebo (Period 1) vs Risankizumab 600mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 23.2 · 95% CI 16.8 to 29.6
  • Placebo (Period 1) vs Risankizumab 1200mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 15.2 · 95% CI 9.3 to 21.2
SecondaryGlobal Outside of US: Percentage of Participants With Endoscopic Remission

Endoscopic remission: SES-CD ≤ 4 and at least a 2 point reduction versus baseline and no subscore greater than 1 in any individual variable

Time frame:
Week 12
Reported as:
Number · percentage of participants
Global Outside of US: Percentage of Participants With Endoscopic Remission
percentage of participantsPlacebo (Period 1)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)
Global Outside of US: Percentage of Participants With Endoscopic Remission9.1 (4.9 to 13.4)24.2 (19.6 to 28.7)23.9 (19.4 to 28.5)
Statistical analysis
  • Placebo (Period 1) vs Risankizumab 600mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 15.1 · 95% CI 9.0 to 21.2
  • Placebo (Period 1) vs Risankizumab 1200mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 15.4 · 95% CI 9.4 to 21.4
SecondaryGlobal Outside of US: Percentage of Participants With Enhanced Clinical Response

Enhanced clinical response: ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission

Time frame:
Week 4
Reported as:
Number · percentage of participants
Global Outside of US: Percentage of Participants With Enhanced Clinical Response
percentage of participantsPlacebo (Period 1)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)
Global Outside of US: Percentage of Participants With Enhanced Clinical Response31.0 (24.1 to 37.9)46.0 (40.7 to 51.3)43.4 (38.1 to 48.6)
Statistical analysis
  • Placebo (Period 1) vs Risankizumab 600mg (Period 1) · Cochran-Mantel-Haenszel · p = 0.001 · Adjusted risk difference: 14.9 · 95% CI 6.2 to 23.5
  • Placebo (Period 1) vs Risankizumab 1200mg (Period 1) · Cochran-Mantel-Haenszel · p = 0.007 · Adjusted risk difference: 11.8 · 95% CI 3.2 to 20.3
SecondaryGlobal Outside of US: Percentage of Participants With Ulcer-Free Endoscopy

Ulcer-free endoscopy: SES-CD ulcerated surface subscore of 0 in subjects with SES-CD ulcerated surface subscore ≥ 1 at Baseline

Time frame:
Week 12
Reported as:
Number · percentage of participants
Global Outside of US: Percentage of Participants With Ulcer-Free Endoscopy
percentage of participantsPlacebo (Period 1)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)
Global Outside of US: Percentage of Participants With Ulcer-Free Endoscopy7.6 (3.6 to 11.5)21.0 (16.6 to 25.4)16.4 (12.4 to 20.3)
Statistical analysis
  • Placebo (Period 1) vs Risankizumab 600mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 13.7 · 95% CI 7.9 to 19.5
  • Placebo (Period 1) vs Risankizumab 1200mg (Period 1) · Cochran-Mantel-Haenszel · p = 0.001 · Adjusted risk difference: 9.1 · 95% CI 3.7 to 14.5
SecondaryGlobal Outside of US: Percentage of Participants With Enhanced Clinical Response

Enhanced clinical response: ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission

Time frame:
Week 12
Reported as:
Number · percentage of participants
Global Outside of US: Percentage of Participants With Enhanced Clinical Response
percentage of participantsPlacebo (Period 1)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)
Global Outside of US: Percentage of Participants With Enhanced Clinical Response41.9 (34.6 to 49.3)62.8 (57.6 to 68.0)64.3 (59.2 to 69.4)
Statistical analysis
  • Placebo (Period 1) vs Risankizumab 600mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 21.0 · 95% CI 12.2 to 29.9
  • Placebo (Period 1) vs Risankizumab 1200mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 21.6 · 95% CI 12.8 to 30.4
SecondaryGlobal Outside of US: Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs), in Participants With EIMs at Baseline

Manifestations of Crohn's disease in areas of the body other than the digestive tract, including eyes, skin, joints, mouth, and liver.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Global Outside of US: Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs), in Participants With EIMs at Baseline
percentage of participantsPlacebo (Period 1)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)
Global Outside of US: Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs), in Participants With EIMs at Baseline20.5 (10.5 to 30.4)38.1 (30.0 to 46.1)43.7 (35.9 to 51.4)
Statistical analysis
  • Placebo (Period 1) vs Risankizumab 600mg (Period 1) · Cochran-Mantel-Haenszel · p = 0.022 · Adjusted risk difference: 14.6 · 95% CI 2.1 to 27.0
  • Placebo (Period 1) vs Risankizumab 1200mg (Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 23.7 · 95% CI 11.1 to 36.3
SecondaryGlobal Outside of US: Percentage of Participants With CD-Related Hospitalization

Participants with at least one admission to the hospital due to Crohn's Disease.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Global Outside of US: Percentage of Participants With CD-Related Hospitalization
percentage of participantsPlacebo (Period 1)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)
Global Outside of US: Percentage of Participants With CD-Related Hospitalization12.0 (7.2 to 16.8)3.3 (1.4 to 5.2)1.8 (0.4 to 3.2)
Statistical analysis
  • Placebo (Period 1) vs Risankizumab 600mg (Period 1) · Mixed-Effect Model Repeat Measurement · p = <0.001 · Ls mean difference: -8.7 · 95% CI -13.9 to -3.5
  • Placebo (Period 1) vs Risankizumab 1200mg (Period 1) · Mixed-Effect Model Repeat Measurement · p = <0.001 · Ls mean difference: -10.2 · 95% CI -15.2 to -5.2
SecondaryGlobal Outside of US: Percentage of Participants Without Draining Fistulas in Participants With Draining Fistulas at Baseline

Participants without draining fistulas at Week 12 in participants who had draining fistulas at baseline.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Global Outside of US: Percentage of Participants Without Draining Fistulas in Participants With Draining Fistulas at Baseline
percentage of participantsPlacebo (Period 1)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)
Global Outside of US: Percentage of Participants Without Draining Fistulas in Participants With Draining Fistulas at Baseline22.2 (0.0 to 49.4)27.8 (7.1 to 48.5)29.2 (11.0 to 47.4)
Statistical analysis
  • Placebo (Period 1) vs Risankizumab 600mg (Period 1) · Mixed-Effect Model Repeat Measurement · p = 1.000 · Ls mean difference: 5.6 · 95% CI -28.6 to 39.7
  • Placebo (Period 1) vs Risankizumab 1200mg (Period 1) · Mixed-Effect Model Repeat Measurement · p = 1.000 · Ls mean difference: 6.9 · 95% CI -25.7 to 39.6
SecondaryGlobal Outside of US: Change From Baseline in Work Productivity and Impairment Questionnaire - Crohn's Disease (WPAI-CD) Overall Work Impairment

WPAI: CD is a questionnaire used to evaluate lost productivity due to CD ; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. Total work productivity impairment takes into account both hours missed due to CD symptoms and the patient's assessment of the degree to which CD affected their productivity while working (overall work impairment \[OWI\]). WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.

Time frame:
Week 12
Reported as:
Least squares mean · units on a scale
Global Outside of US: Change From Baseline in Work Productivity and Impairment Questionnaire - Crohn's Disease (WPAI-CD) Overall Work Impairment
units on a scalePlacebo (Period 1)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)
Global Outside of US: Change From Baseline in Work Productivity and Impairment Questionnaire - Crohn's Disease (WPAI-CD) Overall Work Impairment-8.344 ± 3.5640-17.930 ± 2.3446-20.485 ± 2.3112
Statistical analysis
  • Placebo (Period 1) vs Risankizumab 600mg (Period 1) · Mixed-Effect Model Repeat Measurement · p = 0.024 · Ls mean difference: -9.586 · 95% CI -17.890 to -1.282
  • Placebo (Period 1) vs Risankizumab 1200mg (Period 1) · Mixed-Effect Model Repeat Measurement · p = 0.004 · Ls mean difference: -12.141 · 95% CI -20.390 to -3.892
SecondaryGlobal Outside of US: Change From Baseline in Short Form-36 (SF-36) Physical Component Summary (PCS) Score

The Short Form-36 Health Survey determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement.

Time frame:
Week 12
Reported as:
Least squares mean · units on a scale
Global Outside of US: Change From Baseline in Short Form-36 (SF-36) Physical Component Summary (PCS) Score
units on a scalePlacebo (Period 1)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)
Global Outside of US: Change From Baseline in Short Form-36 (SF-36) Physical Component Summary (PCS) Score5.482 ± 0.59858.394 ± 0.41078.756 ± 0.4071
Statistical analysis
  • Placebo (Period 1) vs Risankizumab 600mg (Period 1) · Mixed-Effect Model Repeat Measurement · p = <0.001 · Ls mean difference: 2.913 · 95% CI 1.512 to 4.313
  • Placebo (Period 1) vs Risankizumab 1200mg (Period 1) · Mixed-Effect Model Repeat Measurement · p = <0.001 · Ls mean difference: 3.275 · 95% CI 1.877 to 4.672

Adverse events

Collected over Treatment-emergent AEs (TEAEs) are from first dose of study drug until 140 days following last dose of study drug. The median duration of treatment for Period 1 with study drug for placebo and Risankizumab was 91.5 and 91 days respectively. For Period 2, the median duration of treatment with study drug for Risankizumab was 141 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Period 1 Placebo IV2/186 (1.1%)28/186 (15.1%)35/186 (18.8%)
Period 1 Risankizumab 600mg IV0/373 (0%)27/373 (7.2%)67/373 (18%)
Period 1 Risankizumab 1200mg IV0/372 (0%)14/372 (3.8%)58/372 (15.6%)
Period 1 Risankizumab Total0/745 (0%)41/745 (5.5%)125/745 (16.8%)
Period 2 Risankizumab 180mg SC0/67 (0%)3/67 (4.5%)4/67 (6%)
Period 2 Risankizumab 360mg SC0/68 (0%)3/68 (4.4%)7/68 (10.3%)
Period 2 Risankizumab 1200mg IV0/67 (0%)4/67 (6%)4/67 (6%)
Period 2 Placebo/Risankizumab 1200mg IV0/76 (0%)4/76 (5.3%)12/76 (15.8%)
Period 2 Risankizumab Total0/278 (0%)14/278 (5%)27/278 (9.7%)
Most frequent serious events
Showing 10 of 71
Most frequent serious events
EventPeriod 1 Placebo IVPeriod 1 Risankizumab 600mg IVPeriod 1 Risankizumab 1200mg IVPeriod 1 Risankizumab TotalPeriod 2 Risankizumab 180mg SCPeriod 2 Risankizumab 360mg SCPeriod 2 Risankizumab 1200mg IVPeriod 2 Placebo/Risankizumab 1200mg IVPeriod 2 Risankizumab Total
CROHN'S DISEASEGastrointestinal disorders15/1865/3732/3727/7451/670/680/670/761/278
ABDOMINAL HERNIAGastrointestinal disorders0/1860/3730/3720/7450/670/681/670/761/278
GASTROINTESTINAL NECROSISGastrointestinal disorders1/1860/3730/3720/7450/670/681/670/761/278
INTESTINAL ISCHAEMIAGastrointestinal disorders0/1860/3730/3720/7450/670/681/670/761/278
INTESTINAL OBSTRUCTIONGastrointestinal disorders2/1861/3730/3721/7451/671/680/671/763/278
SMALL INTESTINAL OBSTRUCTIONGastrointestinal disorders1/1861/3731/3722/7450/670/681/670/761/278
VOMITINGGastrointestinal disorders1/1861/3730/3721/7450/670/681/670/761/278
CHOLECYSTITIS ACUTEHepatobiliary disorders0/1860/3730/3720/7450/670/681/670/761/278
OBSESSIVE-COMPULSIVE DISORDERPsychiatric disorders0/1860/3730/3720/7450/670/681/670/761/278
CALCULUS URINARYRenal and urinary disorders0/1860/3730/3720/7451/670/680/670/761/278
Most frequent other events
Most frequent other events
EventPeriod 1 Placebo IVPeriod 1 Risankizumab 600mg IVPeriod 1 Risankizumab 1200mg IVPeriod 1 Risankizumab TotalPeriod 2 Risankizumab 180mg SCPeriod 2 Risankizumab 360mg SCPeriod 2 Risankizumab 1200mg IVPeriod 2 Placebo/Risankizumab 1200mg IVPeriod 2 Risankizumab Total
HEADACHENervous system disorders8/18624/37320/37244/7451/673/682/675/7611/278
NASOPHARYNGITISInfections and infestations5/18622/37322/37244/7451/671/681/672/765/278
CROHN'S DISEASEGastrointestinal disorders10/1865/3734/3729/7452/671/680/670/763/278
NAUSEAGastrointestinal disorders10/18616/37313/37229/7451/670/680/673/764/278
ANAEMIABlood and lymphatic system disorders5/18611/3739/37220/7450/672/681/674/767/278

Baseline characteristics

Consists of all subjects who received at least 1 dose of study medication.

Age, Categorical
Age, Categorical(Participants)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)Placebo (Period 1)Total
<=18 years3429
Between 18 and 65 years355350175880
>=65 years1518942
Age, Continuous
Age, Continuous(years)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)Placebo (Period 1)Total
Mean38.5 ± 13.2237.6 ± 13.5537.5 ± 13.5137.9 ± 13.40
Sex: Female, Male
Sex: Female, Male(Participants)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)Placebo (Period 1)Total
Female16817393434
Male20519993497
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)Placebo (Period 1)Total
Hispanic or Latino13181041
Not Hispanic or Latino360354176890
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Risankizumab 600mg (Period 1)Risankizumab 1200mg (Period 1)Placebo (Period 1)Total
American Indian or Alaska Native0000
Asian687532175
Native Hawaiian or Other Pacific Islander0112
Black or African American1013932
White291279144714
More than one race4408
Unknown or Not Reported0000
08

Study locations

475 sites
  • Phoenix VA Health Care System /ID# 162267
    Phoenix, Arizona 85012, United States
  • HonorHealth Research Institute - Shea /ID# 161783
    Scottsdale, Arizona 85258, United States
  • Digestive Disease Consultants, A Division of Arizona Digestive Health, P.C /ID# 211883
    Tempe, Arizona 85284-2604, United States
  • University of Arizona /ID# 158469
    Tucson, Arizona 85724, United States
  • Atria Clinical Research /ID# 164740
    Little Rock, Arkansas 72209-7040, United States
  • Newport Huntington Medica /ID# 213033
    Huntington Beach, California 92648-5994, United States
  • United Medical Doctors /ID# 207040
    Los Alamitos, California 90720-3309, United States
  • TLC Clinical Research Inc /ID# 212503
    Los Angeles, California 90048, United States
  • Gastrointestinal Biosciences Clinical Trials, LLC /ID# 162656
    Los Angeles, California 90067-2001, United States
  • United Medical Doctors - Murrieta /ID# 158424
    Murrieta, California 92563, United States
  • Southern CA Research Ctr., Inc /ID# 167875
    Riverside, California 92501, United States
  • University of California, San Francisco /ID# 157143
    San Francisco, California 94158, United States
  • Cedars-Sinai Medical Center-West Hollywood /ID# 163842
    West Hollywood, California 90048, United States
  • Peak Gastroenterology Associates, PC /ID# 165834
    Colorado Springs, Colorado 80907, United States
  • Rocky Mountain Pediatric Gastroenterology /ID# 207169
    Lone Tree, Colorado 80124-6798, United States
  • Western Connecticut Medical Group /ID# 165849
    Danbury, Connecticut 06810-6000, United States
  • Seffner Premier Health Care, PA /ID# 162265
    Brandon, Florida 33510, United States
  • Clinical Research of West Florida, Inc /ID# 204859
    Clearwater, Florida 33765, United States
  • Clinical Research of West Florida, Inc /ID# 207450
    Clearwater, Florida 33765, United States
  • South Lake Pain Institute, Inc /ID# 162825
    Clermont, Florida 34711, United States
  • Universal Axon Clinical Research /ID# 165432
    Doral, Florida 33166, United States
  • Nature Coast Clinical Research - Inverness /ID# 159414
    Inverness, Florida 34452-4717, United States
  • SIH Research Mumtaz, Inc /ID# 163082
    Kissimmee, Florida 34741-4161, United States
  • Alliance Medical Research /ID# 163840
    Lighthouse Point, Florida 33064, United States
  • Cfagi Llc /Id# 201571
    Maitland, Florida 32751-6108, United States
  • Vista Health Research, LLC /ID# 212664
    Miami, Florida 33176-1032, United States
  • ITB Research /ID# 161334
    Miami, Florida 33176, United States
  • Coral Research Clinic /ID# 158549
    Miami, Florida 33186-4643, United States
  • South Florida Research Ph I-IV, Inc. /ID# 161836
    Miami, Florida 33193, United States
  • Gastroenterology Group Naples /ID# 165206
    Naples, Florida 34102, United States
  • Advanced Research Institute, Inc /ID# 161959
    New Port Richey, Florida 34653, United States
  • Endoscopic Research, Inc. /ID# 205901
    Orlando, Florida 32803, United States
  • Omega Research Maitland, LLC /ID# 171081
    Orlando, Florida 32810-2907, United States
  • IMIC Inc. Medical Research /ID# 154943
    Palmetto Bay, Florida 33157, United States
  • Clinical Research Trials of Florida, Inc. /ID# 201014
    Tampa, Florida 33607, United States
  • Gastroenterology Associates of Central Georgia, LLC /ID# 154857
    Macon, Georgia 31201, United States
  • Northwestern University Division of GI/Hepatology /ID# 158283
    Chicago, Illinois 60611-2927, United States
  • The University of Chicago Medical Center /ID# 157141
    Chicago, Illinois 60637-1443, United States
  • NorthShore University HealthSystem /ID# 158287
    Evanston, Illinois 60201, United States
  • Southwest Gastroenterology /ID# 165002
    Oak Lawn, Illinois 60453, United States
  • Cotton-O'Neil Clinical Res Ctr /ID# 154738
    Topeka, Kansas 66606, United States
  • University of Kentucky Chandler Medical Center /ID# 157137
    Lexington, Kentucky 40536, United States
  • University of Louisville /ID# 210521
    Louisville, Kentucky 40202, United States
  • Gastroenterology Associates LLC - Jefferson Hwy /ID# 161956
    Baton Rouge, Louisiana 70809, United States
  • Houma Digestive Health Special /ID# 158286
    Houma, Louisiana 70360, United States
  • Delricht Research /ID# 206542
    New Orleans, Louisiana 70115, United States
  • Nola Research Works, LLC /ID# 161330
    New Orleans, Louisiana 70115, United States
  • Louisana Research Center, LLC /ID# 162236
    Shreveport, Louisiana 71105-6800, United States
  • MGG Group Co, Inc.Chevy Chase Clinical Research /ID# 154839
    Chevy Chase, Maryland 20815, United States
  • Gastro Center of Maryland /ID# 165004
    Columbia, Maryland 21045, United States
  • University of Michigan Health Systems /ID# 157144
    Ann Arbor, Michigan 48109, United States
  • Center for Digestive Health /ID# 154690
    Troy, Michigan 48098-6363, United States
  • Gastroenterology Associates of Western Michigan, PLC d.b.a. West Michigan Clinic /ID# 161328
    Wyoming, Michigan 49519, United States
  • Mayo Clinic - Rochester /ID# 163085
    Rochester, Minnesota 55905-0001, United States
  • Southern Therapy and Advanced Research (STAR) LLC /ID# 162388
    Jackson, Mississippi 39216, United States
  • St. Louis University /ID# 161902
    Saint Louis, Missouri 63104, United States
  • University of Nebraska Medical Center /ID# 210057
    Omaha, Nebraska 68198-2000, United States
  • Las Vegas Medical Research /ID# 160172
    Las Vegas, Nevada 89113, United States
  • Revival Research Institute, Inc /ID# 210984
    Las Vegas, Nevada 89128-3157, United States
  • NY Scientific /ID# 158418
    Brooklyn, New York 11235, United States
  • Saratoga Schenectady Gastroenterology Associates - Burnt Hills /ID# 212036
    Burnt Hills, New York 12027, United States
  • Intercity Advanced Gastroentertology Center /ID# 213399
    Fresh Meadows, New York 11366, United States
  • Duplicate_Long Island Clinical Research /ID# 154836
    Great Neck, New York 11021-5343, United States
  • Digestive Disease Care /ID# 209619
    New Hyde Park, New York 11040, United States
  • North Shore University Hospital /ID# 168736
    New Hyde Park, New York 11040, United States
  • NYU Langone Medical Center /ID# 160171
    New York, New York 10016-6402, United States
  • Columbia Univ Medical Center /ID# 161911
    New York, New York 10032-3725, United States
  • Lenox Hill Hospital /ID# 168465
    New York, New York 10075, United States
  • DiGiovanna Institute for Medical Education & Research /ID# 171118
    North Massapequa, New York 11758, United States
  • Univ NC Chapel Hill /ID# 154840
    Chapel Hill, North Carolina 27514-4220, United States
  • Atrium Health Carolinas Medical Center /ID# 158481
    Charlotte, North Carolina 28203, United States
  • Clinical Trials America /ID# 158484
    Hickory, North Carolina 28601, United States
  • Vidant Multispecialty Clinic - Kinston /ID# 161111
    Kinston, North Carolina 28501-1589, United States
  • Wake Radiology UNC REX Healthcare - Raleigh Office /ID# 154880
    Raleigh, North Carolina 27612, United States
  • Plains Clinical Research Center, LLC /ID# 169715
    Fargo, North Dakota 58104-5925, United States
  • Tri-State Endoscopy /ID# 154933
    Cincinnati, Ohio 45219, United States
  • Cleveland Clinic Main Campus /ID# 208171
    Cleveland, Ohio 44195, United States
  • The Ohio State University /ID# 164709
    Columbus, Ohio 43210, United States
  • Optimed Research, Ltd. /ID# 167901
    Columbus, Ohio 43235, United States
  • Hometown Urgent Care and Resea /ID# 170453
    Dayton, Ohio 45424, United States
  • Great Lakes Medical Research, LLC /ID# 201732
    Mentor, Ohio 44060-6211, United States
  • Hightower Clinical /ID# 211938
    Oklahoma City, Oklahoma 73102, United States
  • Digestive Disease Specialists /ID# 170774
    Oklahoma City, Oklahoma 73112, United States
  • Adult Gastroenterology Associates - Gen 1 Research /ID# 206125
    Tulsa, Oklahoma 74136-7823, United States
  • Northwest Gastroenterology Clinic /ID# 158288
    Portland, Oregon 97210, United States
  • PennState Milton S.Hershey Med /ID# 154883
    Hershey, Pennsylvania 17033, United States
  • Children's Hospital of Pittsburgh of UPMC /ID# 210920
    Pittsburgh, Pennsylvania 15224-1334, United States
  • Digestive Disease Associates, LTD /ID# 208847
    Wyomissing, Pennsylvania 19610-2002, United States
  • Medical University of South Carolina /ID# 212579
    Charleston, South Carolina 29425, United States
  • Gastroenterology Associates, P.A. of Greenville /ID# 154911
    Greenville, South Carolina 29615-3593, United States
  • Rapid City Medical Center - GI Research /ID# 163841
    Rapid City, South Dakota 57701, United States
  • Gastro One /ID# 154742
    Germantown, Tennessee 38138, United States
  • East Tennessee Research Institute /ID# 168737
    Johnson City, Tennessee 37604, United States
  • Duplicate_Clinical Neuroscience Solutions /ID# 164181
    Memphis, Tennessee 38119-4823, United States
  • Vanderbilt University Medical Center /ID# 157138
    Nashville, Tennessee 37232-0011, United States
  • TX Clinical Research Institute /ID# 159410
    Arlington, Texas 76012, United States
  • Inquest Clinical Research /ID# 165695
    Baytown, Texas 77521-2415, United States
  • Texas Digestive Disease Consultants /ID# 209596
    Cedar Park, Texas 78613-5028, United States
  • Texas Digestive Disease Consultants /ID# 209785
    Cedar Park, Texas 78613-5028, United States
  • Baylor Scott & White Center for Inflammatory Bowel Diseases /ID# 201848
    Dallas, Texas 75246, United States

Showing the first 100 of 475 sites across 44 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • D'Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV Jr, Panes J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, Ferrante M. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022 May 28;399(10340):2015-2030. doi: 10.1016/S0140-6736(22)00467-6. PubMed 35644154 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing, please refer to the link below.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Nov 2020, 41 months.

Results were first posted in Jul 2022, 1 year 7 months after primary completion. A results delay was requested in Jul 2021.

Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's 41 months is below that.

Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2017
First posted
Apr 7, 2017
StartActual
May 10, 2017
Primary completionActual
Nov 9, 2020
CompletionActual
Apr 14, 2021
Results delay requested
Jul 16, 2021
Results first posted
Jul 6, 2022
Last update
Jul 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03105128
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Apr 7, 2017
Start date
May 10, 2017
Primary completion
Nov 9, 2020
Completion
Apr 14, 2021
Results posted
Jul 6, 2022
Last update
Jul 6, 2022

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risankizumab

Start the discussion